Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06906926

Harmony TPV EMEA PMS

The Harmony Transcatheter Pulmonary Valve (TPV) System is indicated for use in the management of pediatric and adult congenital heart disease patients with severe pulmonary regurgitation (i.e., severe pulmonary regurgitation as determined by echocardiography and/or pulmonary regurgitant fraction ≥ 30% as determined by cardiac magnetic resonance imaging) who have a native or surgically-repaired right ventricular outflow tract and are clinically indicated for pulmonary valve replacement as judged by the medical team.

Recruiting

Interested in participating?

Request Info

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Rigshospitalet, Copenhagen, Denmark

Loading trial locations.

About this study

Prospective, non-randomized, multi-center, post-market interventional clinical study

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject eligible to receive Harmony TPV System in conformity with Instructions for Use (IFU) and local regulations at time of study enrollment.
  • Subject or subject's parent(s)/legal guardian(s) must be willing and able to consent to participate in the study and will commit to completion of all follow-up requirements

Exclusion criteria

  • Obstruction of the central veins.
  • Planned concomitant branch pulmonary artery stenting at time of implant.
  • Subjects previously treated with an RV-PA conduit or previously implanted bioprosthesis.
  • A major or progressive non-cardiac disease (e.g. liver failure, renal failure, cancer) that results in a life expectancy of less than one year.
  • Planned implantation of the Harmony TPV in the left heart.
  • Echocardiographic evidence of intracardiac mass, thrombus, or vegetation.
  • Pre-existing prosthetic heart valve or prosthetic ring in any position
  • Subject is pregnant as confirmed by a positive pregnancy test before implant procedure for female subjects of childbearing potential.
  • Subjects that are vulnerable as defined in the Section 10.5 Subject Consent

Subject Consent Section excerpt:

  • Vulnerable adults, defined as subjects incapable of giving consent, as assessed per Investigator's opinion and in consideration of vulnerable adult definition per ISO 14155, will not be included in this study.
  • Any subject with mental incompetence (e.g. Alzheimer's, dementia, psychiatric disorders, developmental disorders, chromosomal abnormalities with associated cognitive impairment) should be assessed by the Investigator for vulnerable status. If pediatric or adult subject is deemed by the Investigator mentally incompetent as described above, the subject will not be included in this study.

Treatment and study plan

Certain imaging assessments can be non-Standard of Care

Radiation

Pre-Implant CT, Chest X-Ray at discharge and any related assessments during the following up visit, can be non-standard of care depending on site's / countries.

Primary outcomes

  1. Proportion of subjects without valve reintervention and with acceptable hemodynamic function composite at 6 months as defined by:

    Time frame: 6 months

    • Mean RVOT gradient as measured by continuous-wave Doppler echocardiography ≤40 mmHg AND
    • Pulmonary regurgitant fraction as measured by CMR <20%

Secondary outcomes

  1. Percentage of subjects free from all-cause mortality at 6-months

    Time frame: 6 months

    Described by Kaplan-Meier statistics at 6-months.

  2. Percentage of subjects free from reoperation at 6-months

    Time frame: 6 months

    Described by Kaplan-Meier statistics at 6-months

  3. Percentage of subjects free from catheter reintervention at 6-months

    Time frame: 6 months

    Described by Kaplan-Meier statistics at 6-months.

  4. Percentage of subjects free from TPV dysfunction at 6-months

    Time frame: 6 months

    Described by Kaplan-Meier statistics at 6-months.

  5. Number and percentage of subjects with procedure success at 30-days

    Time frame: 30 days

  6. Number and percentage of subjects with serious device-related adverse events at 6 months

    Time frame: 6 months

    Also described with Kaplan-Meier method for AEs of clinical interest.

Study contacts

Contact information is provided by the study sponsor or research team.

Petra Novakova

CONTACT

[email protected]

+31612591883

Sponsors and collaborators

Lead sponsor

Medtronic Cardiovascular

Industry

Registry information

Official study title

Harmony TPV EMEA Post-Market Study

Important dates

Study start
2025
Primary completion
2027
Study completion
2032
First posted
Apr 2, 2025
Registry last updated
Jul 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.